|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McTiernan A, Jinks RC, Sydes MR, Uscinska
B, Hook JM, van Glabbeke M, Bramwell V, Lewis IJ, Taminiau AH,
Nooij MA, et al: Presence of chemotherapy-induced toxicity predicts
improved survival in patients with localised extremity osteosarcoma
treated with doxorubicin and cisplatin: A report from the European
Osteosarcoma Intergroup. Eur J Cancer. 48:703–712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li XP, Cao GW, Sun Q, Yang C, Yan B, Zhang
MY, Fu YF and Yang LM: Cancer incidence and patient survival rates
among the residents in the Pudong New Area of Shanghai between 2002
and 2006. Chin J Cancer. 32:512–519. 2013.PubMed/NCBI
|
|
6
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Feng Y, Dong YW, Song YN, Xiao JH, Guo XY,
Jiang WL and Lu LG: MicroRNA-449a is a potential predictor of
colitis-associated colorectal cancer progression. Oncol Rep.
40:1684–1694. 2018.PubMed/NCBI
|
|
8
|
Peng X, Zha L, Chen A and Wang Z: HOXA5 is
a tumor suppressor gene that is decreased in gastric cancer. Oncol
Rep. 40:1317–1329. 2018.PubMed/NCBI
|
|
9
|
Zhou B, Li Z, Yang H and He N:
Extracellular miRNAs: Origin, function and biomarkers in hepatic
diseases. J Biomed Nanotechnol. 10:2865–2890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen Z, Tang ZY, He Y, Liu LF, Li DJ and
Chen X: miRNA-205 is a candidate tumor suppressor that targets ZEB2
in renal cell carcinoma. Oncol Res Treat. 37:658–664. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao J, Xu J and Zhang R: MicroRNA-539
inhibits colorectal cancer progression by directly targeting SOX4.
Oncol Lett. 16:2693–2700. 2018.PubMed/NCBI
|
|
12
|
Chen K, Chen Y, Chen Z, Shi Y, He Z, Ding
B, Wang C and Yu L: miR-134 increases the antitumor effects of
cytarabine by targeting Mnks in acute myeloid leukemia cells. Onco
Targets Ther. 11:3141–3147. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Y, Li L, Liu Z, Yuan Q and Lu X:
Downregulation of MiR-431 expression associated with lymph node
metastasis and promotes cell invasion in papillary thyroid
carcinoma. Cancer Biomark. 22:727–732. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu H, Cao B, Zhao Y, Liang H and Hao F:
Upregulated miR-221/222 promotes cell proliferation and invasion
and is associated with invasive features in retinoblastoma. Cancer
Biomark. 22:621–629. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu N, Yang H and Wang H: miR-598 acts as
a tumor suppressor in human gastric cancer by targeting IGF-1R.
Onco Targets Ther. 11:2911–2923. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu W, Wan X, Mu Z, Li F, Wang L, Zhao J
and Huang X: MiR-1256 suppresses proliferation and migration of
non-small cell lung cancer via regulating TCTN1. Oncol Lett.
16:1708–1714. 2018.PubMed/NCBI
|
|
17
|
Arabi L, Gsponer JR, Smida J, Nathrath M,
Perrina V, Jundt G, Ruiz C, Quagliata L and Baumhoer D:
Upregulation of the miR-17-92 cluster and its two paraloga in
osteosarcoma-reasons and consequences. Genes Cancer. 5:56–63.
2014.PubMed/NCBI
|
|
18
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging manual. 7th. New York:
Springer; 2010
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiang J, Wu Y, Li DS, Wang ZY, Shen Q, Sun
TQ, Guan Q and Wang YJ: miR-584 suppresses invasion and cell
migration of thyroid carcinoma by regulating the target oncogene
ROCK1. Oncol Res Treat. 38:436–440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li L and Li S: miR-205-5p inhibits cell
migration and invasion in prostatic carcinoma by targeting ZEB1.
Oncol Lett. 16:1715–1721. 2018.PubMed/NCBI
|
|
22
|
Deng Y and Chen Y: Increased expression of
miR-29a and its prognostic significance in patients with
cholangiocarcinoma. Oncol Res Treat. 40:128–132. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dan B, Luo J, Li K and Chen S: Prognostic
value of miR-375 for survival outcomes in various cancers: A
systematic review and meta-analysis. Oncol Res Treat. 41:47–50.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou W, Hao M, Du X, Chen K, Wang G and
Yang J: Advances in targeted therapy for osteosarcoma. Discov Med.
17:301–307. 2014.PubMed/NCBI
|
|
25
|
Zhang J, Wang D, Xiong J, Chen L and Huang
J: MicroRNA-33a-5p suppresses growth of osteosarcoma cells and is
downregulated in human osteosarcoma. Oncol Lett. 10:2135–2141.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang H, Wang Y, Xu T, Li C, Wu J, He Q,
Wang G, Ding C, Liu K, Tang H and Ji F: Increased expression of
microRNA-148a in osteosarcoma promotes cancer cell growth by
targeting PTEN. Oncol Lett. 12:3208–3214. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mao JH, Zhou RP, Peng AF, Liu ZL, Huang
SH, Long XH and Shu Y: microRNA-195 suppresses osteosarcoma cell
invasion and migration in vitro by targeting FASN. Oncol
Lett. 4:1125–1129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li S, Gao Y, Wang Y, Wang K, Dai ZP, Xu D,
Liu W, Li ZL, Zhang ZD, Yang SH and Yang C: Serum microRNA-17
functions as a prognostic biomarker in osteosarcoma. Oncol Lett.
12:4905–4910. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan W, Li Y, Lim SG and Tan TM:
miR-106b-25/miR-17-92 clusters: Polycistrons with oncogenic roles
in hepatocellular carcinoma. World J Gastroenterol. 20:5962–5972.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Verboon LJ, Obulkasim A, de Rooij JD,
Katsman-Kuipers JE, Sonneveld E, Baruchel A, Trka J, Reinhardt D,
Pieters R, Cloos J, et al: MicroRNA-106b~25 cluster is upregulated
in relapsed MLL-rearranged pediatric acute myeloid leukemia.
Oncotarget. 7:48412–48422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ni X, Xia T, Zhao Y, Zhou W, Wu N, Liu X,
Ding Q, Zha X, Sha J and Wang S: Downregulation of miR-106b induced
breast cancer cell invasion and motility in association with
overexpression of matrix metalloproteinase 2. Cancer Sci.
105:18–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yen CS, Su ZR, Lee YP, Liu IT and Yen CJ:
miR-106b promotes cancer progression in hepatitis B
virus-associated hepatocellular carcinoma. World J Gastroenterol.
22:5183–5192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu M, Zhang YY, Wang HF and Yang GS: The
expression and function of miRNA-106 in pediatric osteosarcoma. Eur
Rev Med Pharmacol Sci. 21:715–722. 2017.PubMed/NCBI
|
|
34
|
Li KK, Xia T, Ma FM, Zhang R, Mao Y, Wang
Y, Zhou L, Lau KM and Ng HK: miR-106b is overexpressed in
medulloblastomas and interacts directly with PTEN. Neuropathol Appl
Neurobiol. 41:145–164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dai F, Liu T, Zheng S, Liu Q, Yang C, Zhou
J, Chen Y, Sheyhidin I and Lu X: MiR-106b promotes migration and
invasion through enhancing EMT via downregulation of Smad 7 in
Kazakh's esophageal squamous cell carcinoma. Tumour Biol.
37:14595–14604. 2016. View Article : Google Scholar : PubMed/NCBI
|
